b Relevant adjuvant studies

Trial	Design	Histology	Chemotherapy	Median TILs	LPBC	Tumors with LPBC phenotype	Outcome (per 10% increase in lymphocye infiltration)	Other outcomes
Loi [52], 2013: patients from the BIG 02-98 trial	Retrosp.	TNBC	Doxorubicin −> CMF or doxorubicin + CP −> CMF vs. doxorubicin + docetaxel −> CMF or doxorubicin −> docetaxel followed by CMF	10% (sTILS) 2% (iTILS)	>50%	10.6%	17% reduction in the risk of relapse 27% reduction in the risk of death	5-year DFS: 92.3% LPBC vs. 61.9% non-LPBC 5-year OS: 92.3% LPBC vs. 71.0% non-LPBC
Loi [53], 2014: patients from the FinHER trial	Retrosp.	TNBC	Docetaxel or VNR ×3 −> FEC ×3	−	>50%	14.3%	21% reduction in the risk of distant recurrence 20% reduction in the risk of death
Adams [54], 2014: patients from ECOG 2197 and ECOG 1199 trials	Retrosp.	TNBC	E2197: doxorubicin + CP vs. docetaxel ×4 E1199: doxorubicin + CP ×4 −> different taxane regimens	10% (sTILS) 0% (iTILS)	>50%	4.4%	18% reduction in the risk of distant recurrence 19% reduction in the risk of death
Pruneri [55], 2016: from the IEO Breast Cancer Database	Retrosp.	TNBC	CMF or CMF + AC	20%	>50%	21.9%	21% reduction in the risk of distant recurrence 21% reduction in the risk of death	10-year DFS (LPBC) 71% 10-year DDFS (LPBC) 84% 10-year OS (LPBC) 96%
Kotoula [56], 2016: patients from 4 prospective trials	Retrosp.	TNBC	Anthracycline − taxane regimens	7% sTILS (all tumors)	>50%	26%	−	7-year DFS: 96.3% (LPBC) vs. 72.8% (non-LPBC) 7-year OS: 100% (LPBC) vs. 76.3% (non-LPBC)

sTILs, stromal tumor-infiltrating lymphocytes; iTIL, intratumoral tumor-infiltrating lymphocytes; DD, dose dense; CP, cyclophosphamide; TAC, docetaxel, doxorubicin, and cyclophosphamide; VNR, vinorelbine; CBDCA, carboplatin; CMF, cyclophosphamide, methotrexate, and fluorouracil; FEC, fluorouracil, epirubicin, and cyclophosphamide; AC, Adriamycin and cyclophosphamide; pCR, pathological complete response; DFS, disease-free survival; DDFS, distant DFS; OS, overall survival.